Evidence map›Paper›PMID 34835765›Full record

ArticleNanomaterials (Basel, Switzerland)2021

Modelling in Synthesis and Optimization of Active Vaccinal Components.

Oana-Constantina Margin, Eva-Henrietta Dulf, Teodora Mocan, Lucian Mocan

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Oana-Constantina MarginDepartment of Automation, Faculty of Automation and Computer Science, Technical University of Cluj-Napoca, Str. Memorandumului 28, 400114 Cluj-Napoca, Romania.
Eva-Henrietta DulfDepartment of Automation, Faculty of Automation and Computer Science, Technical University of Cluj-Napoca, Str. Memorandumului 28, 400114 Cluj-Napoca, Romania.ORCID 0000-0002-6540-6525
Teodora MocanDepartment of Physiology, Iuliu Hațieganu University of Medicine and Pharmacy, 400000 Cluj-Napoca, Romania.
Lucian MocanDepartment of Surgery, 3-rd Surgery Clinic, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj-Napoca, Romania.

Funding

Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii PN-III-P2-2.1-PED-2019-2536, PN-III-P2-2.1-PED-2019-0844; PN-III-P2-2.1-PED-2019-1660
6 · The paper itself

Abstract

Cancer is the second leading cause of mortality worldwide, behind heart diseases, accounting for 10 million deaths each year. This study focusses on adenocarcinoma, which is a target of a number of anticancer therapies presently being tested in medical and pharmaceutical studies. The innovative study for a therapeutic vaccine comprises the investigation of gold nanoparticles and their influence on the immune response for the annihilation of cancer cells. The model is intended to be realized using Quantitative-Structure Activity Relationship (QSAR) methods, explicitly artificial neural networks combined with fuzzy rules, to enhance automated properties of neural nets with human perception characteristics. Image processing techniques such as morphological transformations and watershed segmentation are used to extract and calculate certain molecular characteristics from hyperspectral images. The quantification of single-cell properties is one of the key resolutions, representing the treatment efficiency in therapy of colon and rectum cancerous conditions. This was accomplished by using manually counted cells as a reference point for comparing segmentation results. The early findings acquired are conclusive for further study; thus, the extracted features will be used in the feature optimization process first, followed by neural network building of the required model.

Indexed as

ALOANFISanticancer physiologyimage processingnanomaterials vaccineQSARwatershed segmentation

Identifiers

PMID34835765
PMCPMC8625944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.